Exit

Health Condition

Parkinson’s Disease

About This Condition

Parkinson’s disease results from progressive damage to the nerves in the area of the brain responsible for controlling muscle tone and movement. The damaged cells are those needed to produce a neurotransmitter (chemical messenger in the brain) called dopamine, so people with Parkinson’s disease manufacture inadequate amounts of dopamine. 

Parkinson’s disease occurs primarily, but not exclusively, in the elderly. Parkinson-like symptoms can also be caused by prescription and illicit drugs.

Symptoms

Symptoms include a fixed facial expression, wide-eyed stare with infrequent blinking, fluttering of the eyelids, drooling, illegible handwriting, monotone voice, and rhythmic movement of the fingers, hand, foot, or arm when at rest. People with Parkinson’s disease often have difficulty getting out of bed or a soft chair, and may tend to stand stooped over and walk leaning forward with limited arm-swing and small, shuffling steps. Depression and decreased mental functioning are also common symptoms in advanced stages.

Other Therapies

Surgery that destroys specific areas of the brain is recommended for individuals with severe symptoms that don’t respond to drug therapy. Physical therapy, speech therapy, and aids to daily living, such as railings, non-slip mats, and special chairs, may also be suggested in advanced cases.

References

1. Smythies JR, Halsey JH. Treatment of Parkinson's disease with l-methionine. South Med J 1984;77:1577.

2. Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserizide and carbidopa. Clin Sci 1979;56:89-93.

3. Cotzias GC, Lawrence WH, Papavasiliou PS, Duby SE. Nicotinamide ineffective in parkinsonism. N Engl J Med 1972;287:147.

4. Birkmayer JGD, Vrecko C, Volc D, et al. Nicotinamide adenine dinucleotide (NAD). A new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Neurol Scand 1993;87(Suppl 146):32-5.

5. Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide: New therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996;26:1-9.

6. Wright JV. Interview: Alzheimer's, Parkinson's, NADH research. Jorg Birkmayer, M.D. Nutr Healing 1997;May:5-6.

7. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson's disease with NADH. Acta Neurologica Scand 1994;90:345-7.

8. Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease. Arzneimittelforschung 1976;26:577-9.

9. Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, vol 7. New York: Raven Press, 1986.

10. Coimbra CG, Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Braz J Med Biol Res 2003;36:1409-17.

11. de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 1997;54:762-5.

12. Scheider WL, Hershey LA, Vena JE, et al. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord 1997;12:190-6.

13. Molina JA, de Bustos F, Jimenez-Jimenez FJ, et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J Neural Transm 1997;104:1287-93.

14. Federico A, Battisti C, Formichi P, Dotti MT. Plasma levels of vitamin E in Parkinson's disease. J Neural Transm Suppl1995;267-70.

15. Morens DM, Grandinetti A, Waslien CI, et al. Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology 1996;46:1270-4.

16. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32:S128-32.

17. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 1998;44:S160-6.

18. Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998;50:1900-2.

19. Pappert EJ, Tangney CC, Goetz CG, et al. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 1996;47:1037-42.

20. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.)

21. Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014;71:543–52.

22. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group. J Altern Complement Med 1995;1:249-55.

23. Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, vol 7. New York: Raven Press, 1986.

24. Lemoine P, Robelin N, Sebert P, Mouret J. L-tyrosine: a long term treatment of Parkinson's disease. C R Acad Sci III 1989;309:43-7.

25. Riekkinen P, Rinne UK, Pelliniemi TT, Sonninen V. Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. Arch Neurol 1975;32:25-7.

26. Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res 1989;317:1235-46.

27. Gaby AR. Don't believe everything you read. CounterPoint. Townsend Letter for Doctors Patients 1997;July:125-6 [editorial].

28. Baker AB. Treatment of paralysis agitans with vitamin B6. JAMA 1941;116:2484.

29. Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients. J Neurochem 1972;19(9):2175-81.

30. Leon AS, Spiegel HE, Thomas G, Abrams WB. Pyridoxine antagonism of levodopa in parkinsonism. JAMA 1971;218(13):1924-7.

31. Mars H. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease. Trans Am Neurol Assoc 1973;98:241-5.

32. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013;97:1004-13.

33. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-8.

34. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1 a-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64-8.

35. Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson's disease. Nutr Rev 1994;52:51-8 [review].

36. Reuter I, Engelhardt M, Stecker K, Baas H. Therapeutic value of exercise training in Parkinson's disease. Med Sci Sports Exerc 1999;31:1544-9.

37. Corrigan FM, Wienburg CL, Shore RF, et al. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health 2000;59:229-34.

38. Fleming L, Mann JB, Bean J, et al. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-3.

39. Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 1998;150:339-42.

40. Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 2000;29:323-9.

41. Geusau A, Tschachler E, Meixner M, et al. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet 1999;354:1266-7.

42. Moser GA, McLachlan MS. A non-absorbable dietary fat substitute enhances elimination of persistent lipophilic contaminants in humans. Chemosphere 1999;39:1513-21.

Copyright © 2018 Healthnotes, Inc. All rights reserved. www.healthnotes.com

Learn more about Healthnotes, the company.

The information presented by Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2018.

Drugs used to treat PARKINSONS DISEASE. Select drug name to view medication information and pricing